spironolactone has been researched along with Tachycardia in 15 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hypothesising that selective MR antagonism might also influence atrial ion currents (L-type calcium current [I (Ca,L)], transient outward potassium current [I (to)], sustained outward potassium current [I (sus)]) and their tachycardia-induced remodelling, the effects of an eplerenone treatment were studied in a rabbit model." | 3.76 | Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. ( Bentz, K; Eick, C; Kettering, K; Konior, A; Laszlo, R; Schreieck, J; Schreiner, B, 2010) |
| "Eplerenone suppresses inducibility of sustained atrial tachyarrhythmias, selectively prolongs atrial ERPs, and attenuates LV diastolic remodeling in RVP-induced CHF." | 3.73 | Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. ( Hoit, BD; Martovitz, NL; Ryu, K; Shroff, SC; Stambler, BS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celtik, C | 1 |
| Durmaz, O | 1 |
| Oner, N | 1 |
| Yavuz, T | 1 |
| Gökce, S | 1 |
| Aydogan, A | 1 |
| Nisli, K | 1 |
| Emiroglu, HH | 1 |
| Ömeroglu, RE | 1 |
| Sökücü, S | 1 |
| Barison, A | 1 |
| Aquaro, GD | 1 |
| Passino, C | 1 |
| Falorni, M | 1 |
| Balbarini, A | 1 |
| Lombardi, M | 1 |
| Pasquali, L | 1 |
| Emdin, M | 1 |
| Siciliano, G | 1 |
| Cosín-Aguilar, J | 1 |
| Hernándiz-Martínez, A | 1 |
| Aguilar-Llopis, A | 1 |
| Portolés-Sanz, M | 1 |
| Díez-Gil, JL | 1 |
| Laszlo, R | 1 |
| Bentz, K | 1 |
| Konior, A | 1 |
| Eick, C | 1 |
| Schreiner, B | 1 |
| Kettering, K | 1 |
| Schreieck, J | 1 |
| Shroff, SC | 1 |
| Ryu, K | 1 |
| Martovitz, NL | 1 |
| Hoit, BD | 1 |
| Stambler, BS | 1 |
| Ram, R | 1 |
| Van Wagoner, DR | 1 |
| Carmona-Bayonas, A | 1 |
| Soler, IO | 1 |
| Gómez, FI | 1 |
| Billalabeitia, EG | 1 |
| Saura, HP | 1 |
| Tafalla, MS | 1 |
| Díaz, MP | 1 |
| Kun, IS | 1 |
| Ostrovskaia, VI | 1 |
| Abinder, AA | 1 |
| Kramer, P | 1 |
| Saul, J | 1 |
| Köthe, E | 1 |
| Scheler, F | 1 |
| Birkenhäger, WH | 1 |
| Wester, A | 1 |
| Olesen, KH | 1 |
| Valentin, N | 1 |
| Yeh, BK | 2 |
| Lucchesi, BR | 2 |
| Fleming, JS | 1 |
| Nielsen, CJ | 1 |
| Sung, PK | 1 |
15 other studies available for spironolactone and Tachycardia
| Article | Year |
|---|---|
Investigation of cardiomyopathy in children with cirrhotic and noncirrhotic portal hypertension.
Topics: Adolescent; Antihypertensive Agents; Ascites; Blood Pressure; Cardiomyopathies; Case-Control Studies | 2015 |
Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier.
Topics: Adult; Biomarkers; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Creatine Kinase; Disease | 2009 |
Prevention of myocardial dysfunction by Eplerenon in experimental tachycardiomyopathy.
Topics: Animals; Cardiomyopathies; Eplerenone; Female; Male; Mineralocorticoid Receptor Antagonists; Spirono | 2009 |
Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.
Topics: Animals; Atrial Fibrillation; Calcium Channels, L-Type; Cardiac Pacing, Artificial; Disease Models, | 2010 |
Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure.
Topics: Administration, Oral; Animals; Dogs; Eplerenone; Heart Atria; Heart Conduction System; Heart Failure | 2006 |
Tailored hormonal therapy in secretory adrenocortical cancer.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang | 2007 |
[Debatable questions of strophanthin and spironolactone treatment in certain forms of acute myocardial infarct].
Topics: Adult; Animals; Drug Evaluation; Drug Evaluation, Preclinical; Female; Heart Rate; Hemodynamics; Hum | 1980 |
[Simplified rapid determination of plasma digoxin. Methods and clinical evaluation].
Topics: Anuria; Binding Sites, Antibody; Digoxin; Drug Tolerance; False Positive Reactions; Humans; Iodine R | 1975 |
[A question of logic].
Topics: Diazoxide; Furosemide; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Male; Middle Aged; | 1976 |
Total exchangeable potassium, sodium and chloride in patients with severe valvular heart disease during preparation for cardiac surgery.
Topics: Adult; Aortic Valve Insufficiency; Atrial Fibrillation; Bicarbonates; Blood Proteins; Body Compositi | 1973 |
Letter: Potassium canrenoate and digitalis intoxication.
Topics: Animals; Dogs; Drug Interactions; Electrocardiography; Ouabain; Potassium Chloride; Spironolactone; | 1974 |
Heart failure and cardiac arrhythmias.
Topics: Arrhythmia, Sinus; Arrhythmias, Cardiac; Coronary Disease; Digoxin; Diuretics; Electroconvulsive The | 1974 |
Inability of potassium canrenoate to convert experimentally induced ouabain arrhythmias in the canine heart.
Topics: Animals; Dogs; Electric Stimulation; Electrocardiography; Heart; Male; Methods; Ouabain; Pacemaker, | 1974 |
Prevention and abolition of ouabain-induced ventricular tachycardia by potassium canrenoate in dogs.
Topics: Animals; Digitalis Glycosides; Dogs; Hydroxysteroids; Ketosteroids; Ouabain; Potassium Chloride; Pre | 1972 |